MYC and Miyoshi myopathy: The increased OXPHOS in MM would be a drawback for venetoclax treatment, but the addition of tigecycline to a venetoclax regimen could be a therapeutic opportunity in MM or other B-cell malignancies, especially with a MYC contribution [42].